90% Nocebo (SAMSON) Trial

Why It Matters

By revealing that most statin intolerance stems from expectation rather than the drug itself, the trial highlights a low‑cost opportunity to boost adherence and prevent avoidable heart disease.

Key Takeaways

• 90% of reported statin side effects occurred during placebo periods
• Pill-taking itself, not the drug, drove most symptom reports
• Half of participants resumed statins after seeing their own nocebo data
• True pharmacologic statin myopathy rates likely range between 1%‑5%
• Expectations heavily inflate perceived statin adverse events in clinical practice

Summary

The Samson trial examined 60 patients who had stopped statins due to perceived side effects. Over a 12‑month blinded crossover, participants took a statin for four months, a placebo for four months, and no tablet for the final four months while logging symptoms daily via a phone app.

Results showed that roughly 90% of the symptom burden attributed to statins appeared during the placebo phase, and symptom rates during statin, placebo, and no‑tablet periods were virtually identical. This suggests that the act of taking a pill, regardless of its content, drives most reported adverse effects.

A striking finding was that half of the participants, after reviewing their own data, chose to restart statin therapy. The investigators emphasized that genuine statin‑induced myopathy exists but is rare, estimating a true pharmacologic incidence of only 1%‑5% in controlled trials.

The study underscores the powerful role of patient expectations in drug tolerance, implying that clinicians can improve statin adherence—and thereby cardiovascular outcomes—by addressing the nocebo effect through education and reassurance.

Original Description

The SAMSON trial gave 60 statin-quitters 12 months of randomized blinded treatment: statin, placebo, or nothing. 90% of the symptom burden occurred equally on placebo. Half restarted their statins after seeing the data.